TOLVAPTAN
It is a selective, competitivevasopressin receptor 2 antagonist.It is used in hypervolemic and euvolemic hyponatremia (serum sodium esisted correction with fluid restriction), in pateients with cirrhosis, heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
oral; The usual starting dose is 15 mg administered once daily without regard to meals with gradually increase the dose to 30 mg once daily, after at least 24 hours, to a maximum of 60 mg once daily, upto the correction in serum sodium level is needed. It should not be administered for more than 30 days.
Hypovolemic hyponatremia, urgent need to raise sodium levels, inability of patient to sense or respond to thirst, anuric patient.
Paediatric: safety and efficacy not yet established Pregnancy: category C Lactation: Not known if it is excreted in milk, decision to discontinue drug may be taken depending on importance of drug to mother Elderly: Safety and efficacy similar to young persons.
thirst, dry mouth, asthenia, constipation, polyuria, anorexia and hyperglycemia.
Digoxin, Warfarin, Amiodarone, Furosemide, and Hydrochlorothiazide, Lovastatin.
